N.Y. Middle Schoolers Hospitalized After Ingesting THC Gummies: ‘It's Disturbing'
Nearly a dozen middle school students were hospitalized after consuming THC gummies while on their New York campus, school officials shared.
On Monday, March 3, William Floyd Middle School confirmed the incident in a statement posted on the school's website.
A student at the school 'handed out edible THC gummies to approximately 12 students, who have since fallen ill,' the statement said.
Related: Mom Charged After Kindergartner Mistakenly Took THC Gummies to School, Leading to 4 Hospitalizations
'Eleven of the students have been transported to local hospitals for assistance and one has been released into the custody of a parent,' the statement added. 'We are grateful to our first responders for their quick response, thankful that the students will be treated and hopeful that they will recover quickly.'
The school listed school nurses, Suffolk County Police Department and local EMTs as the first responders who assisted with the affected students.
Related: 17 Middle School Students Ate Mysterious Gummy Bears Before Emergency Drug Overdose Call: Exclusive Details
Officials with the Suffolk County Police Department did not immediately respond to PEOPLE's request for comment.
The students who ingested the THC gummies were between the ages of 13 and 14 years old, NBC New York reported.
Parents were shocked to learn what had happened.
"You don't know where they got it from and what is mixed in there," Felicia Moore told CBS News. "My daughter texted me when it happened and said they were in a lockdown."
"It's disturbing,' Peter Giannetto said, adding, 'my son is in 3rd grade.'
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
According to the Long Island Press, the Suffolk County Police Department will not be pressing charges, stating 'discipline will be handled at the school level.'
'There is no additional information being released on where the gummies came from,' police reportedly said.
Read the original article on People
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
16 hours ago
- Miami Herald
Eric Dane brought to tears during first interview since revealing ALS diagnosis
Eric Dane is opening up about his ALS diagnosis for the first time. The 52-year-old 'Grey's Anatomy' alum, who revealed in April that he was diagnosed with amyotrophic lateral sclerosis (ALS), was brought to tears during a recent interview with 'Good Morning America.' On June 12, GMA shared a 30-second snippet of the interview on social media. 'I wake up every day and I'm immediately reminded that this is happening,' Dane told GMA's Diane Sawyer in the clip. 'It's not a dream.' Despite the diagnosis, Dane remains positive and optimistic about his future. 'I don't think this is the end of my story. I don't feel like this is the end of me,' Dane said in his interview with Diane Sawyer. ALS, also known as Lou Gehrig's disease, is 'a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord,' per The ALS Association. The disease causes a person's brain to lose connection with the muscles in their body, slowly taking away their ability to walk, talk, dress, write, eat, swallow and, eventually, breathe. The average life expectancy once someone is diagnosed with ALS is three years, according to The ALS Association. Dane's interview, which is set to air Monday, June 16, comes two months after the 'Euphoria' star revealed his diagnosis in an exclusive interview with People, published April 10. 'I am grateful to have my loving family by my side as we navigate this next chapter,' he told the outlet. The actor clarified at the time that his diagnosis wasn't stopping him from working and he had already returned to the set of 'Euphoria,' which began production for its third season on April 14, People reported. 'I kindly ask that you give my family and I privacy during this time,' Dane added at the time. The Centers for Disease Control and Prevention (CDC) estimates that less than 30,000 people have ALS in the United States today — and roughly 5,000 new patients are diagnosed every year. There's currently no cure for it and it 'almost always progresses' once it starts, per The ALS Association, but some treatments can help slow its rate of progression and improve the patient's quality of life. Dane shares two children — Billie Beatrice, 15, and Georgia Geraldine, 13 — with his wife, Rebecca Gayheart, per Today.
Yahoo
19 hours ago
- Yahoo
Pharmacy Mixes Up 9-Year-Old's ADHD Medicine, Gives Him Opioid More Powerful Than Morphine
A 9-year-old boy nearly took a powerful opioid stronger than morphine after the local pharmacy gave them a prescription intended for someone else Sarah Paquin says her son usually takes dextroamphetamine for his ADHD, but when her husband went to give their son his medication, he realized it looked different A rep for Shoppers Drug Mart pharmacy in Comox, B.C., tells PEOPLE "the patient was handed the wrong prescription bag"A pharmacy mixed up a nine-year-old's ADHD medicine, giving him a powerfully addictive opioid meant for another customer instead. Sarah Paquin says her 9-year-old son, Declan, takes dextroamphetamine for his ADHD. It's a commonly prescribed stimulant that Declan had been taking for years. As Sarah tells PEOPLE, her husband, David, was about to give him the medication, which they'd picked up from Shoppers Drug Mart pharmacy in Comox, B.C., on May 28. "It's very chaotic in the morning, and if my husband had just been distracted with the other two, or been tired from being up with the baby the night before, this could have ended totally differently," Sarah, who has a 3-year-old and 10-month-old, tells PEOPLE. That's when David looked at the bottle, and realized he was holding someone else's prescription — and it was for hydromorphone. It's a profoundly strong opioid, the U.S. Drug Enforcement Agency explains, with 'potency approximately two to eight times greater than that of morphine and has a rapid onset of action.' As the National Library of Medicine says, 'Accidental ingestion or intentional abuse can lead to overdose and potentially life-threatening respiratory depression.' In a statement to PEOPLE, Loblaw Companies Ltd., which owns Shoppers Drug Mart, said, 'Upon review with the store, we have learned this was a case of human error, one that never should have happened. We have controls in place to minimize risks like this – where the patient was handed the wrong prescription bag – and the Associate will review these with employees to avoid a similar situation in the future. The owner of this location has reached out to the patient's parents to apologize for any undue stress this may have caused, and to outline the corrective steps.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "Thankfully my husband caught it before he took any of it," Sarah says, sharing the pills they'd been given were a 5 mg dose of the powerful opioid. "To do that to a 9-year-old child, it would have been devastating," she tells PEOPLE. She says her family has filed an official complaint with the College of Pharmacists of British Columbia a regulatory agency, and part of the complaint, she says, is "we would like some more strong and strict procedures put in place for picking up such strong heavy medications, especially when they pertain to a child." Her son's medicine, she said, was eventually found in the pharmacy's outgoing box. However, they won't be returning there for their prescriptions. "Trust has been broken," she tells PEOPLE, and urges everyone to inspect their medications before leaving the pharmacy: "Some simple little mistake like that can end somebody's life or cause serious harm." Read the original article on People
Yahoo
20 hours ago
- Yahoo
Weight-Loss Medications Less Effective for People in the 'Real World,' New Study Finds
A new study analyzed patients who used GLP-1 medications in a real-world setting Researchers found that participants lost less weight compared to use in clinical trials They believe discontinuation rates are due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortagesWeight-loss medications like Ozempic and Mounjaro are not as effective in a 'real-world' setting, according to a new study. The study — published June 10 in the Obesity Journal — analyzed nearly 8,000 patients who were classified as having severe obesity. Between 2021 and 2023, they were treated with semaglutide or tirzepatide, injectable GLP-1 medications, in a real-world setting. GLP-1 is short for glucagon-like peptide-1 receptor agonists, which work in the brain to impact satiety. Semaglutide is sold under brand names Ozempic and Wegovy, and tirzepatide is sold under brand names Mounjaro and Zepbound. In a follow-up study, which ended in December 2024, researchers grouped patients who discontinued their obesity medications into those who discontinued early (within 3 months) and late (within 3-12 months). Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! They found that more than 20% of patients discontinued their medications early and 32% discontinued their medications late. Additionally, more than 80% of patients were on lower maintenance dosages of their medications. After a year of treatment, the average weight loss was 3.6% for those who discontinued their treatment early, compared to 6.8% for those who discontinued their treatment late. Those who continued treatment lost about 12% of their body weight. During clinical trials for the GLP-1s, patients lost about 15% to 20% of their body weight. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' Dr. Hamlet Gasoyan, Cleveland Clinic researcher and lead author of the study, said in a statement. The study notes that discontinuation rates during real-world use were higher than those in a clinical trial setting due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortages. Read the original article on People
